Sotera Health (NASDAQ:SHC) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Sotera Health (NASDAQ:SHC) has earned an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $15.70.

SHC has been the subject of a number of analyst reports. Barclays lifted their target price on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price objective on shares of Sotera Health in a research report on Tuesday, August 6th.

Sotera Health Stock Up 1.1 %

Shares of NASDAQ:SHC opened at $16.83 on Wednesday. The business has a fifty day simple moving average of $15.04 and a 200 day simple moving average of $12.88. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44. The firm has a market cap of $4.76 billion, a P/E ratio of 88.58 and a beta of 2.06. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Monday, August 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.15 by $0.04. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The business had revenue of $277.00 million for the quarter, compared to analysts’ expectations of $266.45 million. During the same period in the prior year, the business posted $0.19 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. Analysts predict that Sotera Health will post 0.64 earnings per share for the current year.

Insider Activity

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 55.12% of the company’s stock.

Hedge Funds Weigh In On Sotera Health

A number of large investors have recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in Sotera Health by 43.6% in the 1st quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock valued at $178,865,000 after acquiring an additional 4,525,056 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Sotera Health by 27.0% during the first quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock valued at $145,863,000 after buying an additional 2,579,248 shares during the last quarter. Sessa Capital IM L.P. grew its holdings in Sotera Health by 7.5% during the second quarter. Sessa Capital IM L.P. now owns 4,300,597 shares of the company’s stock worth $51,048,000 after buying an additional 300,597 shares in the last quarter. Darsana Capital Partners LP purchased a new stake in Sotera Health in the 2nd quarter valued at $29,074,000. Finally, P2 Capital Partners LLC lifted its stake in Sotera Health by 27.0% during the 4th quarter. P2 Capital Partners LLC now owns 2,350,000 shares of the company’s stock valued at $39,598,000 after acquiring an additional 500,000 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.